Pharmaceutical

Novartis to strengthen renal disease portfolio with Regulus

Novartis has signed an agreement to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen.

May 2, 2025 - 06:00
Novartis to strengthen renal disease portfolio with Regulus
Novartis has signed an agreement to acquire US-based Regulus Therapeutics and its oligonucleotide, farabursen.
Read the original article

Tags:

Previous Article

GSK remains resilient on tariffs as Q1 sales rise 4%

Next Article

FDA approves J&J’s Imaavy for generalised myasthenia gravis

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Opinion: Current large language models will not fix health care. Here’s what could

Opinion: Current large language models will not fix hea...

Aug 25, 2023

Public health strategies skip patients with rare diseases, says UK study

Public health strategies skip patients with rare diseas...

Feb 11, 2025

STAT+: AbbVie purchases neuroscience developer Cerevel for $8.7 billion

STAT+: AbbVie purchases neuroscience developer Cerevel ...

Dec 7, 2023